Mei Q, Ye Y, Zhu Y-L, Cheng J, Chang X, Liu Y-Y, Li H-R, Li J-B
Department of Infectious Diseases, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):737-44. doi: 10.1007/s10096-014-2285-6. Epub 2014 Nov 26.
The purpose of this study was to test the mutant selection window (MSW) hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin. With the in vitro time-kill studies, S. aureus ATCC 29213 [with a minimal concentration that inhibits colony formation by 99% (MIC99) of 2.2 μg/mL and a mutant prevention concentration (MPC) of 57.6 μg/mL] lost fosfomycin susceptibility at antibiotic concentrations (2×, 4×, and 8× MIC) that are between the lower and upper boundaries of the MSW. In the tissue-cage model, S. aureus was exposed to fosfomycin pharmacokinetics at concentrations below the MIC99, between the MIC99 and the MPC, and above the MPC, respectively. Changes in susceptibility and counts of total and resistant viable bacteria were monitored in tissue-cage fluid obtained daily. However, the selection of resistant mutants was not observed during antibacterial treatment and 48 h after the termination of fosfomycin treatment, regardless of the fosfomycin dosage. Besides, we found no differences between the in vitro-isolated mutant and its sensitive parental strain, which indicates the absence of fitness cost of fosfomycin resistance in S. aureus ATCC 29213. These findings demonstrate that agar plate determinations do not fit the MSW for fosfomycin treatment of rabbits infected with S. aureus ATCC 29213; therefore, the existence of the window must be demonstrated not only in vitro but also in vivo. Further research is needed on the exact mechanism of resistance.
本研究的目的是在体外和体内对暴露于磷霉素的金黄色葡萄球菌进行突变选择窗(MSW)假说测试。通过体外时间杀菌研究,金黄色葡萄球菌ATCC 29213[最小抑菌浓度(MIC99)为2.2μg/mL,突变预防浓度(MPC)为57.6μg/mL]在处于MSW上下限之间的抗生素浓度(2倍、4倍和8倍MIC)下失去了对磷霉素的敏感性。在组织笼模型中,金黄色葡萄球菌分别暴露于低于MIC99、介于MIC99和MPC之间以及高于MPC的磷霉素药代动力学环境中。每天监测组织笼液中敏感性以及总活菌数和耐药活菌数的变化。然而,无论磷霉素剂量如何,在抗菌治疗期间和磷霉素治疗终止后48小时内均未观察到耐药突变体的选择。此外,我们发现体外分离的突变体与其敏感亲本菌株之间没有差异,这表明金黄色葡萄球菌ATCC 29213中磷霉素耐药性不存在适应性代价。这些发现表明,琼脂平板测定不适合用于磷霉素治疗感染金黄色葡萄球菌ATCC 29213的兔子时的MSW;因此,不仅必须在体外而且必须在体内证明该窗口的存在。需要进一步研究耐药的确切机制。